Home › Compound Library › Phenylpiracetam (Phenotropil)

Phenylpiracetam (Phenotropil)

Racetamoral · inferred

Phenylated piracetam derivative with both cognitive and physical performance-enhancing effects. ~100% oral bioavailability, not metabolised, excreted unchanged (~40% urine, ~60% bile/sweat). Banned by WADA as a stimulant. Modulates nicotinic acetylcholine receptors (alpha4beta2) and enhances cerebral blood flow.

Projected serum levels — 100 mg, once daily

Phenylpiracetam (Phenotropil)
Phenylpiracetam (Phenotropil) modeled serum levels, 100 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 100 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 95.1 mg, trough ≈ 14.1 mg body load. Population-based estimate over 15 days for a 100 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Racetam
Route modeled
Oral
Model confidence
inferred
Half-life
7.8 h
Common dose
100 mg
Suggested maximum
300 mg/day
Reference dose range
50–300 mg (single dose)
Suggested cadence
once daily

Documented interactions

  • moderate
    Atomoxetine (Strattera) + Phenylpiracetam (Phenotropil) Stacked effects

    Atomoxetine (Strattera) and Phenylpiracetam (Phenotropil) both push the DAT and NET in the same direction.

  • moderate
    Bupropion (Wellbutrin) + Phenylpiracetam (Phenotropil) Stacked effects

    Bupropion (Wellbutrin) and Phenylpiracetam (Phenotropil) both push the DAT and NET in the same direction.

  • moderate
    Cocaine + Phenylpiracetam (Phenotropil) Stacked effects

    Cocaine and Phenylpiracetam (Phenotropil) both push the DAT and NET in the same direction.

  • moderate
    Contrave (Naltrexone/Bupropion) + Phenylpiracetam (Phenotropil) Stacked effects

    Contrave (Naltrexone/Bupropion) and Phenylpiracetam (Phenotropil) both push the DAT and NET in the same direction.

  • moderate
    d-Amphetamine + Phenylpiracetam (Phenotropil) Stacked effects

    d-Amphetamine and Phenylpiracetam (Phenotropil) both push the DAT and NET in the same direction.

  • moderate
    Duloxetine (Cymbalta) + Phenylpiracetam (Phenotropil) Stacked effects

    Duloxetine (Cymbalta) and Phenylpiracetam (Phenotropil) both push the DAT and NET in the same direction.

Serum checks 26 modeled interaction pairings for phenylpiracetam (phenotropil) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Carphedon at the crossroads: a dangerous drug or a promising psychopharmaceutical? Zvejniece L et al. · Global Journal of Pharmacy & Pharmaceutical Sciences, 2020 DOI

    Comprehensive review of phenylpiracetam (carphedon) pharmacology, including its nootropic, anticonvulsant, antidepressant, and physical performance-enhancing effects, with analysis of its regulatory status.

  2. S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity Zvejniece L et al. · Pharmacology Biochemistry and Behavior, 2017 DOI

    Demonstrated that the S-enantiomer of phenylpiracetam selectively inhibits dopamine transporter (DAT) and reduces body weight gain in mice, revealing enantioselective pharmacological profiles.

  3. Cognitive impairment and nootropic drugs: mechanism of action and spectrum of effects Malykh AG, Sadaie MR · Neurochemical Journal, 2023 DOI

    Review covering phenylpiracetam among other nootropics, describing its mechanism as alpha4beta2 nAChR modulation, improved cerebral blood flow in ischaemic regions, and superior efficacy to piracetam in cognitive models.

3 published studies referenced in the app, each with a plain-language summary.